AGTX.US Agentix Corp
- Market cap
- USD 1.35M
- P/E
- -
- P/B
- 3,587.45x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is AGTX.US undervalued?
Graham numberThe Graham number of Agentix Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Agentix Corp fundamental analysis
No fundamental analysis for Agentix Corp yet.
Agentix Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Agentix Corp
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fa…
Full company profileAgentix Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Agentix Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 43.1K | 2.25K | 0.00 | 0.00 | 1.24K | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -87.9K | -79.1K | -264.00 | -140.00 | 679.00 | - | 0.00 | 0.00 | - | - | - |
| Operating Income | -292K | -334K | -134K | -121K | -344K | - | -1.37M | -745K | -513K | -445K | -327K |
| EBITDA | -292K | -334K | -134K | -121K | -344K | - | -1.37M | -745K | -513K | -445K | -327K |
| Net Income | -296K | -381K | -42.8M | -133K | -364K | - | -1.37M | -585K | -567K | -486K | -417K |
| EPS | -49 | -63 | -3,875 | -0.06 | -0.02 | - | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 11.0K | 7.09K | 2.27K | 93.00 | 93.00 | - | 261K | 106K | 100K | 771.00 | 1.31K |
| Total Liabilities | 870.00 | 72.2K | 55.4K | 126K | 126K | - | 2.51M | 2.67M | 3.20M | 3.60M | 3.81M |
| Shareholders' Equity | 10.1K | -65.1K | -53.1K | -126K | -126K | - | -2.25M | -2.56M | -3.10M | -3.60M | -3.81M |
| Cash & Short-term Investments | 6.95K | 3.69K | 2.13K | 93.00 | 93.00 | - | 12.4K | 6.54K | 4.48K | 771.00 | 1.31K |
| Total Debt | - | 67.4K | 45.7K | 110K | 110K | - | 50.0K | 143K | 243K | 353K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.6K | -76.4K | -51.6K | -62.0K | -369K | -25.2K | -88.5K | -110K | -125K | -109K | -59.8K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.00 |
| Free Cash Flow | -12.6K | -76.4K | -51.6K | -62.0K | -369K | - | -88.5K | -110K | -125K | -109K | -59.8K |
| Ratios | |||||||||||
| ROE | -2,914.1% | - | - | - | - | - | - | - | - | - | - |
| ROA | -2,683.9% | -5,373.7% | -1,889,137.0% | -142,636.6% | -391,302.2% | - | -525.7% | -550.1% | -565.5% | -62,987.8% | -31,813.9% |
| Net Profit Margin | -685.2% | -16,937.8% | - | - | -29,347.7% | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Agentix Corp dividends
Agentix Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 100:1 on Feb 25, 2020.
Who owns Agentix Corp
- Insiders 20.91%
- Institutions 0.00%
- Public & others 79.09%
- Shares outstanding 40.1M
- Free float 31.7M
Agentix Corp company profile
- Company name
- Agentix Corp
- Ticker
- AGTX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- March
- Address
- 32932 Pacific Coast Highway, Dana Point, CA, United States, 92629
- Phone
- 321 299 2014
- Website
- agentixcorp.com
About Agentix Corp
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company has licensing agreement with National Health Research Institute and Research Triangle Institute. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.
Agentix Corp management
3- Mr. Riazul HudaCEO, CFO & Director · born 1969
- Mr. Martin SchroederChief Scientific Officer & Member of Scientific Advisory Board · born 1953
- Mr. David FieneFinancial Controller